Market Overview:
The global neurologic disorders therapeutics market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of neurologic disorders, rising geriatric population, and technological advancements in the field of neurology. Based on type, the global neurologic disorders therapeutics market is segmented into central nervous system (CNS) and peripheral nervous system (PNS). CNS diseases are more common than PNS diseases and account for a larger share of the global neurologic disorders therapeutics market. Based on application, paralysis, muscle weakness, poor coordination, loss of sensation, seizures, confusion pain and altered levels of consciousness are some major segments in this market. Among these applications paralysis accounts for a larger share owing to its high prevalence rate across all regions.
Product Definition:
Neurologic Disorders Therapeutics is the branch of medicine that deals with the diagnosis and treatment of disorders of the nervous system. It is important because it helps to treat conditions that can cause pain, disability, or death.
Central Nervous System (CNS):
The Central Nervous System (CNS) is a network of neurological pathways that arise from and pass through the brain. The CNS comprises the brain, spinal cord, nerves, and neuromuscular junction. The CNS controls all the body’s activities such as vision, hearing, feeling touch; therefore it is also known as “the feel” or “feeling machine”.
Peripheral Nervous System (PNS):
The peripheral nervous system is a network of nerves that can be separated from the central nervous system. The PNS consists of cranial nerves, spinal cord and nerve roots, and peripheral nerves. Peripheral neuropathy is one of the most common forms affecting people globally with an estimated annual cost to GDP ratio of USD 50 billion (1% global GDP).
Application Insights:
Paralysis held the largest share of 26.0% in 2017 owing to the rising incidence of spinal cord injuries and other causes of paraplegia. According to WHO, around 60-80 people worldwide are paralysed every year due to road traffic accidents or violence. Increasing healthcare costs, need for better care facilities and management policies for neurological disorders are some factors responsible for segment growth during the forecast period.
The muscle weakness segment is expected to witness significant growth over the forecast period due largely on an increase in geriatric population susceptible to muscle cramps and spastic muscles which may lead to disability or death if not treated properly. According these statistics by WHO, around 70 million people above 60 years old were registered globally as well as approximately 50 million were found above 80 years old globally (in 2016).
Regional Analysis:
North America dominated the global market in 2017. The presence of well-established healthcare facilities, favorable reimbursement policies, and increasing awareness levels amongst patients are some of the factors responsible for its growth. Moreover, neurological diseases are highly prevalent in this region as a result of unhealthy lifestyles and genetic vulnerability which has led to increased adoption of preventative measures such as early diagnosis.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising disposable income coupled with growing health awareness among people especially geriatric population resulting in higher incidence rates for various neurological disorders such as Parkinson’s disease (PD) and multiple sclerosis (MS). In addition, rapidly developing economy along with improving healthcare infrastructure is also anticipated to contribute towards regional market development during the same period. Furthermore, increasing investments by major pharmaceutical companies for R&D activities on CNS therapeutics will drive revenue generation over next eight years.
Growth Factors:
- Increasing incidence of neurological disorders
- Growing awareness about available treatments for neurological disorders
- Rising demand for better and more effective therapies for neurological disorders
- Technological advancements in the field of neurology and neuroscience
- increasing funding for research on neurologic disorders
Scope Of The Report
Report Attributes
Report Details
Report Title
Neurologic Disorders Therapeutics Market Research Report
By Type
Central Nervous System (CNS), Peripheral Nervous System (PNS)
By Application
Paralysis, Muscle Weakness, Poor Coordination, Loss of Sensation, Seizures, Confusion, Pain and Altered Levels of Consciousness
By Companies
Biogen Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Novartis AG, Pfizer Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
223
Number of Tables & Figures
157
Customization Available
Yes, the report can be customized as per your need.
Global Neurologic Disorders Therapeutics Market Report Segments:
The global Neurologic Disorders Therapeutics market is segmented on the basis of:
Types
Central Nervous System (CNS), Peripheral Nervous System (PNS)
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Paralysis, Muscle Weakness, Poor Coordination, Loss of Sensation, Seizures, Confusion, Pain and Altered Levels of Consciousness
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Biogen Inc.
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson Services Inc.
- Novartis AG
- Pfizer Inc.
Highlights of The Neurologic Disorders Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Central Nervous System (CNS)
- Peripheral Nervous System (PNS)
- By Application:
- Paralysis
- Muscle Weakness
- Poor Coordination
- Loss of Sensation
- Seizures
- Confusion
- Pain and Altered Levels of Consciousness
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Neurologic Disorders Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Neurologic Disorders Therapeutics is a specialty pharmaceutical company that develops and commercializes therapies for neurologic disorders. The company's products include drugs to treat Alzheimer's disease, multiple sclerosis, stroke, and other neurologic conditions.
Some of the major players in the neurologic disorders therapeutics market are Biogen Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Novartis AG, Pfizer Inc..
The neurologic disorders therapeutics market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Neurologic Disorders Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Neurologic Disorders Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Neurologic Disorders Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Neurologic Disorders Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Neurologic Disorders Therapeutics Market Size & Forecast, 2018-2028
4.5.1 Neurologic Disorders Therapeutics Market Size and Y-o-Y Growth
4.5.2 Neurologic Disorders Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Neurologic Disorders Therapeutics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Neurologic Disorders Therapeutics Market Size Forecast by Type
5.2.1 Central Nervous System (CNS)
5.2.2 Peripheral Nervous System (PNS)
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Neurologic Disorders Therapeutics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Neurologic Disorders Therapeutics Market Size Forecast by Applications
6.2.1 Paralysis
6.2.2 Muscle Weakness
6.2.3 Poor Coordination
6.2.4 Loss of Sensation
6.2.5 Seizures
6.2.6 Confusion
6.2.7 Pain and Altered Levels of Consciousness
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Neurologic Disorders Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Neurologic Disorders Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Neurologic Disorders Therapeutics Analysis and Forecast
9.1 Introduction
9.2 North America Neurologic Disorders Therapeutics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Neurologic Disorders Therapeutics Market Size Forecast by Type
9.6.1 Central Nervous System (CNS)
9.6.2 Peripheral Nervous System (PNS)
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Neurologic Disorders Therapeutics Market Size Forecast by Applications
9.10.1 Paralysis
9.10.2 Muscle Weakness
9.10.3 Poor Coordination
9.10.4 Loss of Sensation
9.10.5 Seizures
9.10.6 Confusion
9.10.7 Pain and Altered Levels of Consciousness
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Neurologic Disorders Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Europe Neurologic Disorders Therapeutics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Neurologic Disorders Therapeutics Market Size Forecast by Type
10.6.1 Central Nervous System (CNS)
10.6.2 Peripheral Nervous System (PNS)
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Neurologic Disorders Therapeutics Market Size Forecast by Applications
10.10.1 Paralysis
10.10.2 Muscle Weakness
10.10.3 Poor Coordination
10.10.4 Loss of Sensation
10.10.5 Seizures
10.10.6 Confusion
10.10.7 Pain and Altered Levels of Consciousness
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Neurologic Disorders Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Neurologic Disorders Therapeutics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Neurologic Disorders Therapeutics Market Size Forecast by Type
11.6.1 Central Nervous System (CNS)
11.6.2 Peripheral Nervous System (PNS)
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Neurologic Disorders Therapeutics Market Size Forecast by Applications
11.10.1 Paralysis
11.10.2 Muscle Weakness
11.10.3 Poor Coordination
11.10.4 Loss of Sensation
11.10.5 Seizures
11.10.6 Confusion
11.10.7 Pain and Altered Levels of Consciousness
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Neurologic Disorders Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Latin America Neurologic Disorders Therapeutics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Neurologic Disorders Therapeutics Market Size Forecast by Type
12.6.1 Central Nervous System (CNS)
12.6.2 Peripheral Nervous System (PNS)
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Neurologic Disorders Therapeutics Market Size Forecast by Applications
12.10.1 Paralysis
12.10.2 Muscle Weakness
12.10.3 Poor Coordination
12.10.4 Loss of Sensation
12.10.5 Seizures
12.10.6 Confusion
12.10.7 Pain and Altered Levels of Consciousness
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Neurologic Disorders Therapeutics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Neurologic Disorders Therapeutics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Neurologic Disorders Therapeutics Market Size Forecast by Type
13.6.1 Central Nervous System (CNS)
13.6.2 Peripheral Nervous System (PNS)
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Neurologic Disorders Therapeutics Market Size Forecast by Applications
13.10.1 Paralysis
13.10.2 Muscle Weakness
13.10.3 Poor Coordination
13.10.4 Loss of Sensation
13.10.5 Seizures
13.10.6 Confusion
13.10.7 Pain and Altered Levels of Consciousness
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Neurologic Disorders Therapeutics Market: Competitive Dashboard
14.2 Global Neurologic Disorders Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Biogen Inc.
14.3.2 F. Hoffmann-La Roche Ltd.
14.3.3 Johnson & Johnson Services Inc.
14.3.4 Novartis AG
14.3.5 Pfizer Inc.
